IDM Pharma, Inc. (IDMI)

[bowonwing]

IDM's ace in the hole- is the ten year monopoly granted by the EMEA for Mepact. Whatever business entity (IDM or a buyer/partner of the company) which markets Mepact has an artificial restriction upon the extension of its use. Any monopoly power is clearly capital (revenues) to its individual owner. The degree (exclusive) and duration (ten years) is an intangible any business owner would covet because of its predictability.

Scientific research and its technical application are carried on at a cost and with the expectation of a return in some form. The uncertainty here, as tzm has posted, is what the pricing structure will be for Mepact, as well as the costs to produce the product.

At least cancer patients will have access to Mepact to help fight their battles. With Palo Alto on watch, I believe the value of IDM's ten year monopoly on Mepact will be recognized and rewarded by the market. Let us not forget what certainties we DO have with IDM, which is the artificial restriction by the EMEA upon Mepacts use. As of 5/8/09 IDM is at about $1.70, and I believe the market is not properly valuing this monopoly. Time will tell. JMHO